When to Order Imaging for Radiologic Management of Pulmonary Nodules and Masses: ACR Appropriateness Decoded

When to Order Imaging for Radiologic Management of Pulmonary Nodules and Masses: ACR Appropriateness Decoded

A patient’s chest CT, ordered for an unrelated reason, reveals a 1.5 cm solid pulmonary nodule. The patient has a significant smoking history. Is this an incidental finding to be watched, or does it require immediate tissue sampling? Deciding the next step in managing pulmonary nodules and masses involves weighing the risks of malignancy against the risks of invasive procedures. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria for the radiologic management of these common findings, helping you choose the right path forward based on evidence-based guidelines from the Interventional Radiology panel.

What Does ACR Radiologic Management of Pulmonary Nodules and Masses Cover?

This ACR topic focuses on the subsequent management steps for pulmonary nodules and masses that have already been identified, typically on computed tomography (CT) of the chest. The criteria evaluate the appropriateness of various interventional and diagnostic procedures, including percutaneous biopsy, endobronchial ultrasound (EBUS), ablation, and surgical options. The scenarios are designed for adult patients and stratify recommendations based on nodule characteristics (e.g., solid, ground glass, size), stability over time, location (central vs. peripheral), and patient-specific factors like smoking history, prior malignancy, and surgical fitness. These guidelines are not intended for the initial detection or screening for pulmonary nodules, which is covered under separate criteria for lung cancer screening. They are specifically for clinicians deciding on the workup or treatment of a known lesion.

What Imaging Should I Order for Radiologic Management of Pulmonary Nodules and Masses? Recommendations by Clinical Scenario

The appropriate next step for a pulmonary nodule depends heavily on its characteristics and the clinical context. The ACR provides guidance for several common scenarios.

For an adult who smokes with a stable 1 to 3 cm solitary solid pulmonary nodule that has been unchanged for two years, invasive procedures are generally discouraged. The ACR rates Follow-up imaging only as May be appropriate. The stability over a two-year period strongly suggests a benign etiology, making the risks of biopsy or intervention outweigh the potential benefits. In this context, percutaneous lung biopsy is rated May be appropriate (Disagreement), reflecting that it might be considered in select high-risk cases but is not routine. Other interventions like EBUS, ablation, or surgery are all rated Usually not appropriate.

In contrast, for a serially enlarging solitary solid pulmonary nodule (now 1 to 3 cm) in a person who smokes, the guidelines shift decisively toward tissue diagnosis. Both Percutaneous lung biopsy and Endobronchial ultrasound and biopsy are rated Usually appropriate. Growth is a key indicator of potential malignancy, necessitating a definitive diagnosis to guide treatment. The choice between percutaneous and endobronchial approaches often depends on the nodule’s location. For more on the initial imaging, see our guide on CT Lung Cancer Screening (Low-Dose). Follow-up imaging alone is Usually not appropriate in this setting.

Nodule location is critical. For a 1 to 3 cm solitary solid pulmonary nodule near the hilum found on an initial screening CT in a person who smokes, Endobronchial ultrasound and biopsy is Usually appropriate. The central location makes it highly accessible to an endobronchial approach. A Percutaneous lung biopsy is considered May be appropriate but can be riskier for central lesions. For a serially enlarging peripheral nodule (1 to 3 cm) in a patient with a high risk of poor surgical outcome, Percutaneous lung biopsy is Usually appropriate due to its accessibility and lower risk compared to surgery. In this high-risk, non-surgical candidate, non-curative options like Stereotactic body radiotherapy and Percutaneous ablation lung are also rated May be appropriate.

The patient’s history is also a major factor. For a 1 to 3 cm peripheral nodule in a patient with a previously treated nonpulmonary primary malignancy, the primary concern is metastasis. Therefore, Percutaneous lung biopsy is Usually appropriate to confirm the histology. For a persistent 1 to 3 cm solitary ground glass pulmonary nodule suspicious for primary lung adenocarcinoma, Percutaneous lung biopsy is also Usually appropriate to obtain a diagnosis, as these lesions carry a high suspicion for malignancy.

ACR Imaging Recommendations Table

Adult vs. Pediatric Radiologic Management of Pulmonary Nodules and Masses Imaging: Radiation Dose Tradeoffs

The ACR variants for this topic are exclusively focused on adult populations, and no specific pediatric radiation relative level (RRL) is provided. This reflects the clinical reality that the epidemiology and management of pulmonary nodules differ significantly between adults and children. In adults, particularly those with a smoking history, the primary concern is often primary lung cancer or metastatic disease. In children, pulmonary nodules are far more likely to be infectious or inflammatory in origin, with malignancy being rare.

When imaging children, the ALARA (As Low As Reasonably Achievable) principle is paramount. The threshold for invasive procedures like biopsy is generally much higher, and management often favors a conservative approach with close clinical and imaging follow-up. If a pediatric patient requires evaluation for a pulmonary nodule, consultation with a pediatric pulmonologist and radiologist is essential to develop a diagnostic plan that minimizes cumulative radiation exposure while appropriately addressing the clinical concern. The diagnostic algorithms and appropriateness criteria for pediatric cases are distinct and are not covered by this adult-focused guideline.

Imaging Protocol Details for Radiologic Management of Pulmonary Nodules and Masses

Once you’ve decided on the right study, the protocol matters. Executing a high-quality diagnostic study is critical for accurate characterization and biopsy planning. Our protocol guides cover technique, contrast, and reading principles for the studies recommended above. For detailed procedural and imaging parameters, explore these related guides:

• CT Lung Cancer Screening (Low-Dose)
• Ultrasound Abdomen Complete

Tools to Help You Order the Right Study

Navigating imaging guidelines can be complex. GigHz offers several tools designed to support evidence-based clinical decisions. These resources can help you select the most appropriate study and communicate effectively with patients about radiation.

For scenarios not covered in this article, the ACR Appropriateness Criteria Lookup provides a comprehensive, searchable interface for the full library of ACR guidelines. It helps you quickly find evidence-based recommendations for hundreds of clinical variants.

To ensure studies are performed correctly, the Imaging Protocol Library offers detailed, step-by-step protocols for a wide range of CT, MRI, and ultrasound examinations. This is a valuable resource for standardizing imaging techniques across an institution.

When discussing imaging with patients, especially concerning CT scans, the Radiation Dose Calculator is a useful tool. It helps estimate cumulative radiation exposure from various imaging studies, facilitating informed conversations about the risks and benefits of a recommended procedure.

What is the difference between a percutaneous lung biopsy and an endobronchial ultrasound (EBUS) biopsy?

A percutaneous lung biopsy is performed by an interventional radiologist, who guides a needle through the skin and chest wall into the lung nodule using imaging guidance (usually CT). It is most effective for peripheral nodules. An EBUS biopsy is performed by a pulmonologist or interventional pulmonologist, who passes an ultrasound-equipped bronchoscope into the airways to visualize and biopsy nodules or lymph nodes adjacent to the bronchi. It is most effective for central nodules and mediastinal lymph nodes.

Why is follow-up imaging alone sometimes appropriate for a stable nodule?

A solid pulmonary nodule that has not changed in size, shape, or density over a two-year period has a very high probability of being benign. In this situation, the small but real risks associated with an invasive biopsy (such as pneumothorax or bleeding) are generally considered to outweigh the extremely low risk of the nodule being a slow-growing cancer. Continued surveillance may still be warranted depending on the patient’s overall risk profile.

When is percutaneous ablation considered for a lung nodule?

Percutaneous ablation (using techniques like radiofrequency, microwave, or cryoablation) is a treatment option, not a primary diagnostic tool. It is typically considered for patients with proven or highly suspected early-stage lung cancer who are not candidates for surgery due to poor lung function or other comorbidities. It is rated as May be appropriate for enlarging peripheral nodules in high-risk surgical patients but is Usually not appropriate as a first-line step without a tissue diagnosis.

What defines a “high risk of poor surgical outcome”?

This is a clinical determination based on a patient’s overall health and comorbidities. Factors include severe chronic obstructive pulmonary disease (COPD), poor pulmonary function tests (e.g., low FEV1), significant cardiovascular disease, advanced age, and poor functional status. These patients may not be able to tolerate the physiological stress of thoracic surgery and lung resection, making less invasive options like stereotactic radiation or percutaneous ablation more appropriate treatment considerations.

Why is biopsy usually appropriate for a new nodule in a patient with a history of cancer?

In a patient with a known primary malignancy elsewhere in the body, a new pulmonary nodule is suspicious for metastatic disease. However, these patients are also at risk for developing a new primary lung cancer or having a benign nodule. A biopsy is crucial to establish a definitive diagnosis, as the treatment for a lung metastasis can be very different from the treatment for a new primary lung cancer or a benign process like an infection.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026